Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Biotherapy & Radiopharmaceuticals|May 5, 2009
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancerJózsef Horti, Anders Widmark, Arnulf Stenzl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancerRodryg Ramlau, Radj Gervais, Maciej Krzakowski, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancerRaymond P Abratt, Jung Sin Lee, Ji Youn Han, et al.Journal of Global Oncology|November 3, 2017
Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access ProgramBernardo L Rapoport, Daniel A Vorobiof, Lydia M Dreosti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trialRichard H de Boer, Óscar Arrieta, Chih-Hsin Yang, et al.Lung Cancer Management|August 11, 2020
Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancerBernardo L Rapoport, Annette J Theron, Daniel A Vorobiof, et al.Blood Advances|December 4, 2020
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A Moccia, Christian Taverna, Sämi Schär, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Giovanni Martinelli, Felicitas Hitz, et al.Breast (Edinburgh, Scotland)|June 19, 2024
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)Fatima Cardoso, Shani Paluch-Shimon, Eva Schumacher-Wulf, et al.Pageof 2